Impact of bile acids on the growth of human cholangiocarcinoma via FXR

Journal of Hematology and Oncology

Volumn 4, Issue , 2011, Pages

  Dai, Jiaqi ^a   Wang, Hongxia ^a   Shi, Yihui ^b   Dong, Ying ^a   Zhang, Yinxin ^a   Wang, Jian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SRI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; BILE ACID; BILE ACID CONJUGATE; CHENODEOXYCHOLIC ACID; FARNESOID X RECEPTOR; GLYCOCHENODEOXYCHOLIC ACID; GUGGULSTERONE; MESSENGER RNA; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; ISOXAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE ACID BLOOD LEVEL; BILE DUCT CARCINOMA; CANCER INHIBITION; CANCER PATIENT; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR GROWTH; WESTERN BLOTTING; ANIMAL; CELL LINE; DOSE RESPONSE; DRUG EFFECT; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ANIMALS; BILE ACIDS AND SALTS; CELL LINE; CHOLANGIOCARCINOMA; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOXAZOLES; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 80053927730     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-4-41     Document Type: Article

References (32)

1. Recent advances in gastrointestinal oncology-updates and insights from the 2009 annual meeting of the American Society of Clinical Oncology. Javle Milind, Hsueh Chung-Tsen, Journal of Hematology & Oncology 2010 3 11 21 10.1186/1756-8722-3-11 21993689
2. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Sirica AE, Hepatology 2005 41 5 15 10.1002/hep.20537 15690474 (Pubitemid 40066375)
3. Bile acids induce overexpression of homeobox gene CDX-2 and vascular endothelial growth factor (VEGF) in human Barrett's esophageal mucosa and adenocarcinoma cell line. Burnat G, Rau T, Elshimi E, Hahn EG, Konturek PC, Scand J Gastroenterol 2007 42 1460 1465 10.1080/00365520701452209 17852856 (Pubitemid 350125549)
4. Analyzing the regulation of metabolic pathways in human breast cancer. Schramm G, Surmann EM, Wiesberg S, Oswald M, Reinelt G, Eils R, König R, BMC Med Genomics 2010 3 39 10.1186/1755-8794-3-39 20831783
5. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Trauner M, Fickert P, Halilbasic E, Moustafa T, Wien Med Wochenschr 2008 158 542 548 10.1007/s10354-008-0592-1 18998069
6. Bile acids as endogenous etiologic agents in gastrointestinal cancer. Bernstein H, Bernstein C, Payne CM, Dvorak K, World J Gastroenterol 2009 15 3329 3340 10.3748/wjg.15.3329 19610133
7. Bile acids stimulate invasion and haptotaxis in human colorectal cancer cells through activation of multiple oncogenic signalling pathways. Debruyne PR, Bruyneel EA, Karaguni IM, Li X, Flatau G, Müller O, Zimber A, Gespach C, Mareel MM, Oncogene 2002 21 6740 6750 10.1038/sj.onc.1205729 12360401 (Pubitemid 35221916)
8. Bile acid induces expression of COX-2 through the homeodomain transcription factor CDX1 and orphan nuclear receptor SHP in human gastric cancer cells. Park MJ, Kim KH, Kim HY, Kim K, Cheong J, Carcinogenesis 2008 29 2385 2393 10.1093/carcin/bgn207 18775915
9. Differential effects of deoxycholic acid and taurodeoxycholic acid on NF-kappa B signal transduction and IL-8 gene expression in colonic epithelial cells. Mühlbauer M, Allard B, Bosserhoff AK, Kiessling S, Herfarth H, Rogler G, Schölmerich J, Jobin C, Hellerbrand C, Am J Physiol Gastrointest Liver Physiol 2004 286 1000 1008 10.1152/ajpgi.00338.2003 14726307 (Pubitemid 38715663)
10. Activation of the interleukin-6/STAT3 antiapoptotic pathway in esophageal cells by bile acids and low pH: relevance to Barrett's esophagus. Dvorak K, Chavarria M, Payne CM, Ramsey L, Crowley-Weber C, Dvorakova B, Dvorak B, Bernstein H, Holubec H, Sampliner RE, Bernstein C, Prasad A, Green SB, Garewal H, Clin Cancer Res 2007 13 5305 5313 10.1158/1078-0432.CCR-07-0483 17875759 (Pubitemid 47510354)
11. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Wehbe H, Henson R, Meng F, Mize-Berge J, Patel T, Cancer Res 2006 66 10517 10524 10.1158/0008-5472.CAN-06- 2130 17079474 (Pubitemid 44799774)
12. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Wang H, Chen J, Hollister K, Sowers LC, Forman BM, Mol Cell 1999 3 543 553 10360171 (Pubitemid 29268438)
13. Differential regulation of bile acid homeostasis by the farnesoid × receptor in liver and intestine. Kim I, Ahn SH, Inagaki T, Choi M, Ito S, Guo GL, Kliewer SA, Gonzalez FJ, J Lipid Res 2007 48 2664 2672 10.1194/jlr.M700330- JLR200 17720959 (Pubitemid 350272851)
14. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA, Proc Natl Acad Sci USA 2006 103 1006 1011 10.1073/pnas.0506982103 16410358 (Pubitemid 43212212)
15. The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: hype or hope? Trauner M, Hepatology 2004 40 260 263 10.1002/hep.20294 15239110 (Pubitemid 38868945)
16. Farnesoid × receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W, Hepatology 2008 48 1632 1643 10.1002/hep.22519 18972444
17. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid × receptor. Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W, Cancer Res 2007 67 863 867 10.1158/0008-5472.CAN-06-1078 17283114
18. Spontaneous hepatocarcinogenesis in farnesoid × receptor-null mice. Kim I, Morimura K, Shah Y, Yang Q, Ward JM, Gonzalez FJ, Carcinogenesis 2007 28 940 946 17183066 (Pubitemid 47072176)
19. Farnesoid × receptor activates transcription of the phospholipid pump MDR3. Huang L, Zhao A, Lew JL, Zhang T, Hrywna Y, Thompson JR, de Pedro N, Royo I, Blevins RA, Peláez F, Wright SD, Cui J, J Biol Chem 2003 278 51085 51090 10.1074/jbc.M308321200 14527955 (Pubitemid 38020343)
20. Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Modica S, Murzilli S, Salvatore L, Schmidt DR, Moschetta A, Cancer Res 2008 68 9589 9594 10.1158/0008-5472.CAN-08-1791 19047134
21. Effects of bile acids on expression of interleukin-6 and cell viability in QBC939 cell line. Wang J, Dai JQ, Zhang CF, Zhonghua Wai Ke Za Zhi 2010 48 919 23 21055228
22. Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference. Wang J, Shi YQ, Yi J, Ye S, Wang LM, Xu YP, He M, Kong XM, J Dig Dis 2008 9 228 37 10.1111/j.1751-2980.2008.00352.x 18959596
23. Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid × receptor-mediated estrogen receptor activation. Journe F, Laurent G, Chaboteaux C, Nonclercq D, Durbecq V, Larsimont D, Body JJ, Breast Cancer Res Treat 2008 107 49 61 17333335 (Pubitemid 350179595)
24. Retinoic acid as cause of cell proliferation or cell growth inhibition depending on activation of one of two different nuclear receptors. Wolf G, Nutr Rev 2008 66 55 59 10.1111/j.1753-4887.2007.00006.x 18254885 (Pubitemid 351666662)
25. An update on the pathobiological relevance of nuclear receptors for cancers of the head and neck. Stauber RH, Wünsch D, Knauer SK, Fetz V, Histol Histopathol 2010 25 1093 1104 20552557
26. The farnesoid × receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Swales KE, Korbonits M, Carpenter R, Walsh DT, Warner TD, Bishop-Bailey D, Cancer Res 2006 66 10120 10126 10.1158/0008-5472.CAN-06-2399 17047076 (Pubitemid 44672066)
27. Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Modica S, Murzilli S, Salvatore L, Schmidt DR, Moschetta A, Cancer Res 2008 68 9589 9594 10.1158/0008-5472.CAN-08-1791 19047134
28. Farnesoid × receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Li YT, Swales KE, Thomas GJ, Warner TD, Bishop-Bailey D, Arterioscler Thromb Vasc Biol 2007 27 2606 2611 10.1161/ATVBAHA.107.152694 18029909 (Pubitemid 350158912)
29. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. Frémin Christophe, Meloche Sylvain, Journal of Hematology & Oncology 2010 3 8 10.1186/1756-8722-3-8 21993689
30. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. Yuan RuiRong, Kay Andrea, Berg William J, Lebwohl David, Journal of Hematology & Oncology 2009 2 45 56 10.1186/1756-8722-2-45 21993689
31. The clinical potential of microRNAs. Budhu Anuradha, Ji Junfang, Wang Xin W, Journal of Hematology & Oncology 2010 3 37 10.1186/1756-8722-3-37 21993689
32. Dysregulation of miR-15a and miR-214 in human pancreatic cancer. Zhang Xing J, Ye Hua, Zeng Cheng W, He Bo, Zhang Hua, Chen Yue Q, Journal of Hematology & Oncology 2010 3 46 10.1186/1756-8722-3-46 21993689